{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T04:16:11Z","timestamp":1793333771144,"version":"4.5.0"},"reference-count":163,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T00:00:00Z","timestamp":1757289600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T00:00:00Z","timestamp":1757289600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Gastroenterol Hepatol"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1038\/s41575-025-01112-5","type":"journal-article","created":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T06:39:45Z","timestamp":1757399985000},"page":"696-707","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Dopaminergic signalling in gastrointestinal health and disease"],"prefix":"10.1038","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8859-0361","authenticated-orcid":false,"given":"Trisha S.","family":"Pasricha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2298-0623","authenticated-orcid":false,"given":"Subhash","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,8]]},"reference":[{"key":"1112_CR1","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/S0165-1838(00)00127-2","volume":"81","author":"JB Furness","year":"2000","unstructured":"Furness, J. B. Types of neurons in the enteric nervous system. J. Auton. Nerv. Syst. 81, 87\u201396 (2000).","journal-title":"J. Auton. Nerv. Syst."},{"key":"1112_CR2","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1210\/jcem-43-3-668","volume":"43","author":"H Leblanc","year":"1976","unstructured":"Leblanc, H., Lachelin, G. C. L., Abu-Fadil, S. & Yen, S. S. C. Effects of dopamine infusion on pituitary hormone secretion in humans. J. Clin. Endocrinol. Metab. 43, 668\u2013674 (1976).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1112_CR3","first-page":"787","volume":"73","author":"W Birkmayer","year":"1961","unstructured":"Birkmayer, W. & Hornykiewicz, O. The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia [German]. Wien. Klin. Wochenschr. 73, 787\u2013788 (1961).","journal-title":"Wien. Klin. Wochenschr."},{"key":"1112_CR4","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/S0140-6736(75)91762-6","volume":"305","author":"MO Thorner","year":"1975","unstructured":"Thorner, M. O. Dopamine is an important neurotransmitter in the autonomic nervous SysteM. Lancet 305, 662\u2013665 (1975).","journal-title":"Lancet"},{"key":"1112_CR5","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/S0002-8703(76)80216-5","volume":"91","author":"W Pawlik","year":"1976","unstructured":"Pawlik, W., Mailman, D., Shanbour, L. L. & Jacobson, E. D. Dopamine effects on the intestinal circulation. Am. Heart J. 91, 325\u2013331 (1976).","journal-title":"Am. Heart J."},{"key":"1112_CR6","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1161\/01.RES.24.5.699","volume":"24","author":"HL Brooks","year":"1969","unstructured":"Brooks, H. L., Stein, P. D., Matson, J. L. & Hyland, J. W. Dopamine-induced alterations in coronary hemodynamics in dogs. Circ. Res. 24, 699\u2013704 (1969).","journal-title":"Circ. Res."},{"key":"1112_CR7","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1172\/JCI104996","volume":"43","author":"RH Mcdonald","year":"1964","unstructured":"Mcdonald, R. H., Goldberg, L. I., Mcnay, J. L. & Tuttle, E. P. Effect of dopamine in man: augmentation of sodium excretion, glomerular filtration rate, and renal plasma flow. J. Clin. Invest. 43, 1116\u20131124 (1964).","journal-title":"J. Clin. Invest."},{"key":"1112_CR8","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.1016\/0024-3205(87)90464-4","volume":"41","author":"DE Hernandez","year":"1987","unstructured":"Hernandez, D. E., Mason, G. A., Walker, C. H. & Valenzuela, J. E. Dopamine receptors in human gastrointestinal mucosa. Life Sci. 41, 2717\u20132723 (1987).","journal-title":"Life Sci."},{"key":"1112_CR9","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/S0016-5085(76)80149-7","volume":"70","author":"S Rattan","year":"1976","unstructured":"Rattan, S. & Goyal, R. K. Effect of dopamine on the esophageal smooth muscle in vivo. Gastroenterology 70, 377\u2013381 (1976).","journal-title":"Gastroenterology"},{"key":"1112_CR10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0298660","volume":"19","author":"NC Galinelli","year":"2024","unstructured":"Galinelli, N. C. et al. Evidence for dopamine production and distribution of dopamine D2 receptors in the equine gastrointestinal mucosa and pancreas. PLoS ONE19, e0298660 (2024).","journal-title":"PLoS ONE"},{"key":"1112_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/1478-811X-11-34","volume":"11","author":"J Meiser","year":"2013","unstructured":"Meiser, J., Weindl, D. & Hiller, K. Complexity of dopamine metabolism. Cell Commun. Signal. 11, 34 (2013).","journal-title":"Cell Commun. Signal."},{"key":"1112_CR12","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1523\/JNEUROSCI.07-01-00279.1987","volume":"7","author":"DA Lewis","year":"1987","unstructured":"Lewis, D. A., Campbell, M. J., Foote, S. L., Goldstein, M. & Morrison, J. H. The distribution of tyrosine hydroxylase-immunoreactive fibers in primate neocortex is widespread but regionally specific. J. Neurosci. 7, 279\u2013290 (1987).","journal-title":"J. Neurosci."},{"key":"1112_CR13","first-page":"21","volume":"55","author":"T H\u00f6kfelt","year":"1977","unstructured":"H\u00f6kfelt, T., Johansson, O., Fuxe, K., Goldstein, M. & Park, D. Immunohistochemical studies on the localization and distribution of monoamine neuron systems in the rat brain II. Tyrosine hydroxylase in the telencephalon. Med. Biol. 55, 21\u201340 (1977).","journal-title":"Med. Biol."},{"key":"1112_CR14","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1111\/j.1471-4159.2011.07339.x","volume":"118","author":"E Bromek","year":"2011","unstructured":"Bromek, E., Haduch, A., Go\u0142embiowska, K. & Daniel, W. A. Cytochrome P450 mediates dopamine formation in the brain in vivo. J. Neurochem. 118, 806\u2013815 (2011).","journal-title":"J. Neurochem."},{"key":"1112_CR15","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1097\/00008571-199902000-00005","volume":"9","author":"A Atkinson","year":"1999","unstructured":"Atkinson, A. et al. CYP2D6 is associated with Parkinson\u2019s disease but not with dementia with Lewy bodies or Alzheimer\u2019s disease. Pharmacogenetics 9, 31\u201335 (1999).","journal-title":"Pharmacogenetics"},{"key":"1112_CR16","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/S0022-510X(97)00179-2","volume":"153","author":"SJ McCann","year":"1997","unstructured":"McCann, S. J., Pond, S. M., James, K. M. & Le Couteur, D. G. The association between polymorphisms in the cytochrome P-450 2D6 gene and Parkinson\u2019s disease: a case-control study and meta-analysis. J. Neurol. Sci. 153, 50\u201353 (1997).","journal-title":"J. Neurol. Sci."},{"key":"1112_CR17","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.tins.2007.03.002","volume":"30","author":"SD Iversen","year":"2007","unstructured":"Iversen, S. D. & Iversen, L. L. Dopamine: 50 years in perspective. Trends Neurosci. 30, 188\u2013193 (2007).","journal-title":"Trends Neurosci."},{"key":"1112_CR18","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.neubiorev.2010.02.001","volume":"35","author":"S Ikemoto","year":"2010","unstructured":"Ikemoto, S. Brain reward circuitry beyond the mesolimbic dopamine system: a neurobiological theory. Neurosci. Biobehav. Rev. 35, 129\u2013150 (2010).","journal-title":"Neurosci. Biobehav. Rev."},{"key":"1112_CR19","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.pbb.2011.05.002","volume":"99","author":"LC Bidwell","year":"2011","unstructured":"Bidwell, L. C., McClernon, F. J. & Kollins, S. H. Cognitive enhancers for the treatment of ADHD. Pharmacol. Biochem. Behav. 99, 262\u2013274 (2011).","journal-title":"Pharmacol. Biochem. Behav."},{"key":"1112_CR20","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/0168-0102(93)90035-O","volume":"16","author":"T Hattori","year":"1993","unstructured":"Hattori, T. Conceptual history of the nigrostriatal dopamine system. Neurosci. Res. 16, 239\u2013262 (1993).","journal-title":"Neurosci. Res."},{"key":"1112_CR21","doi-asserted-by":"publisher","first-page":"T101","DOI":"10.1530\/JOE-15-0213","volume":"226","author":"DR Grattan","year":"2015","unstructured":"Grattan, D. R. 60 years of neuroendocrinology: the hypothalamo-prolactin axis. J. Endocrinol. 226, T101\u2013T122 (2015).","journal-title":"J. Endocrinol."},{"key":"1112_CR22","doi-asserted-by":"publisher","DOI":"10.1172\/JCI143775","volume":"131","author":"A Singh","year":"2021","unstructured":"Singh, A., Dawson, T. M. & Kulkarni, S. Neurodegenerative disorders and gut-brain interactions. J. Clin. Invest. 131, e143775 (2021).","journal-title":"J. Clin. Invest."},{"key":"1112_CR23","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s40120-018-0091-2","volume":"7","author":"M Mamelak","year":"2018","unstructured":"Mamelak, M. Parkinson\u2019s disease, the dopaminergic neuron and gammahydroxybutyrate. Neurol. Ther. 7, 5\u201311 (2018).","journal-title":"Neurol. Ther."},{"key":"1112_CR24","doi-asserted-by":"publisher","first-page":"3731","DOI":"10.1523\/JNEUROSCI.1478-20.2021","volume":"41","author":"BJ Ryan","year":"2021","unstructured":"Ryan, B. J. et al. REST protects dopaminergic neurons from mitochondrial and \u03b1-synuclein oligomer pathology in an alpha synuclein overexpressing BAC-transgenic mouse model. J. Neurosci. 41, 3731\u20133746 (2021).","journal-title":"J. Neurosci."},{"key":"1112_CR25","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nrn.2016.178","volume":"18","author":"DJ Surmeier","year":"2017","unstructured":"Surmeier, D. J., Obeso, J. A. & Halliday, G. M. Selective neuronal vulnerability in Parkinson disease. Nat. Rev. Neurosci. 18, 101\u2013113 (2017).","journal-title":"Nat. Rev. Neurosci."},{"key":"1112_CR26","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.tins.2010.09.004","volume":"33","author":"LL Venda","year":"2010","unstructured":"Venda, L. L., Cragg, S. J., Buchman, V. L. & Wade-Martins, R. \u03b1-Synuclein and dopamine at the crossroads of Parkinson\u2019s disease. Trends Neurosci. 33, 559\u2013568 (2010).","journal-title":"Trends Neurosci."},{"key":"1112_CR27","doi-asserted-by":"publisher","first-page":"3702","DOI":"10.1016\/j.febslet.2015.10.021","volume":"589","author":"D Haddad","year":"2015","unstructured":"Haddad, D. & Nakamura, K. Understanding the susceptibility of dopamine neurons to mitochondrial stressors in Parkinson\u2019s disease. FEBS Lett. 589, 3702\u20133713 (2015).","journal-title":"FEBS Lett."},{"key":"1112_CR28","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41392-023-01588-0","volume":"8","author":"C Gao","year":"2023","unstructured":"Gao, C., Jiang, J., Tan, Y. & Chen, S. Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets. Signal. Transduct. Target. Ther. 8, 359 (2023).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"1112_CR29","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.parkreldis.2009.08.007","volume":"16","author":"CH Hawkes","year":"2010","unstructured":"Hawkes, C. H., Del Tredici, K. & Braak, H. A timeline for Parkinson\u2019s disease. Parkinsonism Relat. Disord. 16, 79\u201384 (2010).","journal-title":"Parkinsonism Relat. Disord."},{"key":"1112_CR30","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1097\/MCG.0000000000001961","volume":"58","author":"TS Pasricha","year":"2024","unstructured":"Pasricha, T. S., Guerrero-Lopez, I. L. & Kuo, B. Management of gastrointestinal symptoms in Parkinson\u2019s disease: a comprehensive review of clinical presentation, workup, and treatment. J. Clin. Gastroenterol. 58, 211\u2013220 (2024).","journal-title":"J. Clin. Gastroenterol."},{"key":"1112_CR31","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.actbio.2021.03.071","volume":"132","author":"AJ Bindas","year":"2021","unstructured":"Bindas, A. J., Kulkarni, S., Koppes, R. A. & Koppes, A. N. Parkinson\u2019s disease and the gut: models of an emerging relationship. Acta Biomater. 132, 325\u2013344 (2021).","journal-title":"Acta Biomater."},{"key":"1112_CR32","doi-asserted-by":"publisher","first-page":"3864","DOI":"10.1210\/jcem.82.11.4339","volume":"82","author":"G Eisenhofer","year":"1997","unstructured":"Eisenhofer, G. et al. Substantial production of dopamine in the human gastrointestinal tract. J. Clin. Endocrinol. Metab. 82, 3864\u20133871 (1997).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1112_CR33","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1002\/cne.10599","volume":"459","author":"M Anlauf","year":"2003","unstructured":"Anlauf, M., Sch\u00e4fer, M. K. H., Eiden, L. & Weihe, E. Chemical coding of the human gastrointestinal nervous system: cholinergic, VIPergic, and catecholaminergic phenotypes. J. Comp. Neurol. 459, 90\u2013111 (2003).","journal-title":"J. Comp. Neurol."},{"key":"1112_CR34","first-page":"G1044","volume":"273","author":"K Shichijo","year":"1997","unstructured":"Shichijo, K., Sakurai-Yamashita, Y., Sekine, I. & Taniyama, K. Neuronal release of endogenous dopamine from corpus of guinea pig stomach. Am. J. Physiol. 273, G1044\u2013G1050 (1997).","journal-title":"Am. J. Physiol."},{"key":"1112_CR35","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1161\/01.CIR.93.9.1667","volume":"93","author":"G Eisenhofer","year":"1996","unstructured":"Eisenhofer, G. et al. Cardiac sympathetic nerve function in congestive heart failure. Circulation 93, 1667\u20131676 (1996).","journal-title":"Circulation"},{"key":"1112_CR36","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1182\/blood-2006-01-028423","volume":"109","author":"M Cosentino","year":"2007","unstructured":"Cosentino, M. et al. Human CD4+CD25+ regulatory T cells selectively express tyrosine hydroxylase and contain endogenous catecholamines subserving an autocrine\/paracrine inhibitory functional loop. Blood 109, 632\u2013642 (2007).","journal-title":"Blood"},{"key":"1112_CR37","doi-asserted-by":"publisher","first-page":"3062","DOI":"10.4049\/jimmunol.1103096","volume":"188","author":"C Prado","year":"2012","unstructured":"Prado, C. et al. Stimulation of dopamine receptor D5 expressed on dendritic cells potentiates Th17-mediated immunity. J. Immunol. 188, 3062\u20133070 (2012).","journal-title":"J. Immunol."},{"key":"1112_CR38","doi-asserted-by":"publisher","first-page":"3258","DOI":"10.1111\/bph.15047","volume":"177","author":"XY Feng","year":"2020","unstructured":"Feng, X. Y. et al. Source of dopamine in gastric juice and luminal dopamine-induced duodenal bicarbonate secretion via apical dopamine D2 receptors. Br. J. Pharmacol. 177, 3258\u20133272 (2020).","journal-title":"Br. J. Pharmacol."},{"key":"1112_CR39","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.neuroscience.2008.02.033","volume":"153","author":"YM Tian","year":"2008","unstructured":"Tian, Y. M. et al. Alteration of dopaminergic markers in gastrointestinal tract of different rodent models of Parkinson\u2019s disease. Neuroscience 153, 634\u2013644 (2008).","journal-title":"Neuroscience"},{"key":"1112_CR40","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1073\/pnas.0604049104","volume":"104","author":"AJ Rashid","year":"2007","unstructured":"Rashid, A. J. et al. D1-D2 dopamine receptor heterooligomers with unique pharmacology are coupled to rapid activation of Gq\/11 in the striatum. Proc. Natl Acad. Sci. USA 104, 654\u2013659 (2007).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1112_CR41","doi-asserted-by":"publisher","first-page":"21377","DOI":"10.1073\/pnas.0903676106","volume":"106","author":"A Hasbi","year":"2009","unstructured":"Hasbi, A. et al. Calcium signaling cascade links dopamine D1-D2 receptor heteromer to striatal BDNF production and neuronal growth. Proc. Natl Acad. Sci. USA 106, 21377\u201321382 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1112_CR42","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.coph.2009.10.001","volume":"10","author":"R Maggio","year":"2010","unstructured":"Maggio, R. & Millan, M. J. Dopamine D2-D3 receptor heteromers: pharmacological properties and therapeutic significance. Curr. Opin. Pharmacol. 10, 100\u2013107 (2010).","journal-title":"Curr. Opin. Pharmacol."},{"key":"1112_CR43","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1002\/acn3.51274","volume":"8","author":"P Yang","year":"2021","unstructured":"Yang, P. et al. Dopamine D1 + D3 receptor density may correlate with parkinson disease clinical features. Ann. Clin. Transl. Neurol. 8, 224\u2013237 (2021).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"1112_CR44","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1146\/annurev.pharmtox.39.1.313","volume":"39","author":"DR Sibley","year":"1999","unstructured":"Sibley, D. R. New insights into dopaminergic receptor function using antisense and genetically altered animals. Annu. Rev. Pharmacol. Toxicol. 39, 313\u2013341 (1999).","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"1112_CR45","doi-asserted-by":"publisher","DOI":"10.1111\/nmo.13811","volume":"32","author":"MG Zizzo","year":"2020","unstructured":"Zizzo, M. G., Bellanca, A., Amato, A. & Serio, R. Opposite effects of dopamine on the mechanical activity of circular and longitudinal muscle of human colon. Neurogastroenterol. Motil. 32, e13811 (2020).","journal-title":"Neurogastroenterol. Motil."},{"key":"1112_CR46","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1111\/j.1440-1746.2012.07100.x","volume":"27","author":"XB Liu","year":"2012","unstructured":"Liu, X. B. & Liu, J. F. Expression of dopamine receptors in human lower esophageal sphincter. J. Gastroenterol. Hepatol. 27, 945\u2013950 (2012).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"1112_CR47","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s10620-008-0335-6","volume":"54","author":"P Kashyap","year":"2009","unstructured":"Kashyap, P., Micci, M. A., Pasricha, S. & Pasricha, P. J. The D2\/D3 agonist PD128907 (R-(+)-trans-3,4a,10b-tetrahydro-4-propyl-2H,5H-[1]benzopyrano[4,3-b]-1,4-oxazin-9-ol) inhibits stimulated pyloric relaxation and spontaneous gastric emptying. Dig. Dis. Sci. 54, 57\u201362 (2009).","journal-title":"Dig. Dis. Sci."},{"key":"1112_CR48","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/S0022-3565(25)20869-2","volume":"251","author":"GB Glavin","year":"1989","unstructured":"Glavin, G. B. Activity of selective dopamine DA1 and DA2 agonists and antagonists on experimental gastric lesions and gastric acid secretion. J. Pharmacol. Exp. Ther. 251, 726\u2013730 (1989).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"1112_CR49","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1007\/BF01537589","volume":"35","author":"GB Glavin","year":"1990","unstructured":"Glavin, G. B. & Szabo, S. Dopamine in gastrointestinal disease. Dig. Dis. Sci. 35, 1153\u20131161 (1990).","journal-title":"Dig. Dis. Sci."},{"key":"1112_CR50","doi-asserted-by":"publisher","first-page":"eaau6296","DOI":"10.1126\/scitranslmed.aau6296","volume":"11","author":"Haak","year":"2019","unstructured":"Haak, et al. Selective YAP\/TAZ inhibition in fibroblasts via dopamine receptor D1 agonism reverses fibrosis. Sci. Transl. Med. 11, eaau6296 (2019).","journal-title":"Sci. Transl. Med."},{"key":"1112_CR51","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.3892\/or.2014.3068","volume":"31","author":"J Mu","year":"2014","unstructured":"Mu, J. et al. Thioridazine, an antipsychotic drug, elicits potent antitumor effects in gastric cancer. Oncol. Rep. 31, 2107\u20132114 (2014).","journal-title":"Oncol. Rep."},{"key":"1112_CR52","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.3892\/or.2016.5313","volume":"37","author":"C Zhang","year":"2017","unstructured":"Zhang, C. et al. Thioridazine elicits potent antitumor effects in colorectal cancer stem cells. Oncol. Rep. 37, 1168\u20131174 (2017).","journal-title":"Oncol. Rep."},{"key":"1112_CR53","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/0928-4257(93)90011-H","volume":"87","author":"GB Glavin","year":"1993","unstructured":"Glavin, G. B. Vulnerability to stress ulcerogenesis in rats differing in anxiety: a dopaminergic correlate. J. Physiol. Paris. 87, 239\u2013243 (1993).","journal-title":"J. Physiol. Paris."},{"key":"1112_CR54","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/0278-5846(92)90073-N","volume":"16","author":"GB Glavin","year":"1992","unstructured":"Glavin, G. B. Central dopamine involvement in experimental gastrointestinal injury. Prog. Neuropsychopharmacol. Biol. Psychiatry 16, 217\u2013221 (1992).","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"1112_CR55","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.physbeh.2004.01.004","volume":"81","author":"J Landeira-Fernandez","year":"2004","unstructured":"Landeira-Fernandez, J. & Grijalva, C. V. Participation of the substantia nigra dopaminergic neurons in the occurrence of gastric mucosal erosions. Physiol. Behav. 81, 91\u201399 (2004).","journal-title":"Physiol. Behav."},{"key":"1112_CR56","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/S0016-5085(60)80137-0","volume":"38","author":"DA Brodie","year":"1960","unstructured":"Brodie, D. A. & Hanson, H. M. A study of the factors involved in the production of gastric ulcers by the restraint technique. Gastroenterology 38, 353\u2013360 (1960).","journal-title":"Gastroenterology"},{"key":"1112_CR57","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/0361-9230(80)90300-7","volume":"5","author":"DL Innes","year":"1980","unstructured":"Innes, D. L. & Tansy, M. F. Gastric mucosal ulceration associated with electrochemical stimulation of the limbic brain. Brain Res. Bull. 5, 33\u201336 (1980).","journal-title":"Brain Res. Bull."},{"key":"1112_CR58","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/BF01536330","volume":"34","author":"DE Hernandez","year":"1989","unstructured":"Hernandez, D. E., Walker, C. H., Valenzuela, J. E. & Mason, G. A. Increased dopamine receptor binding in duodenal mucosa of duodenal ulcer patients. Dig. Dis. Sci. 34, 543\u2013547 (1989).","journal-title":"Dig. Dis. Sci."},{"key":"1112_CR59","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1016\/0024-3205(84)90454-5","volume":"35","author":"DE Hernandez","year":"1984","unstructured":"Hernandez, D. E. et al. Prevention of stress-induced gastric ulcers by dopamine agonists in the rat. Life Sci. 35, 2453\u20132458 (1984).","journal-title":"Life Sci."},{"key":"1112_CR60","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1007\/BF01297139","volume":"36","author":"P Sikiric","year":"1991","unstructured":"Sikiric, P. et al. Dopamine agonists prevent duodenal ulcer relapse. A comparative study with famotidine and cimetidine. Dig. Dis. Sci. 36, 905\u2013910 (1991).","journal-title":"Dig. Dis. Sci."},{"key":"1112_CR61","doi-asserted-by":"publisher","first-page":"190","DOI":"10.3109\/00365528909091158","volume":"162","author":"H Tanimura","year":"1989","unstructured":"Tanimura, H. et al. The effect of DQ-2511, a newly synthesized anti-ulcer drug, on the gastric mucosal hemodynamics and ulceration in rats. Scand. J. Gastroenterol. Suppl. 162, 190\u2013193 (1989).","journal-title":"Scand. J. Gastroenterol. Suppl."},{"key":"1112_CR62","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1007\/BF02779180","volume":"25","author":"Y Nagahata","year":"1990","unstructured":"Nagahata, Y., Urakawa, T. & Saitoh, Y. Effect of dopamine on prostaglandin E2 content in gastric mucosa. Gastroenterol. Jpn. 25, 681\u2013684 (1990).","journal-title":"Gastroenterol. Jpn."},{"key":"1112_CR63","doi-asserted-by":"publisher","first-page":"C393","DOI":"10.1152\/ajpcell.00261.2017","volume":"316","author":"Y Li","year":"2019","unstructured":"Li, Y. et al. Dopamine promotes colonic mucus secretion through dopamine D5 receptor in rats. Am. J. Physiol. Cell Physiol. 316, C393\u2013C403 (2019).","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"1112_CR64","doi-asserted-by":"publisher","first-page":"842","DOI":"10.5694\/j.1326-5377.1965.tb72277.x","volume":"1","author":"RR Strang","year":"1965","unstructured":"Strang, R. R. The association of gastro-duodenal ulceration and Parkinson\u2019s disease. Med. J. Aust. 1, 842\u2013843 (1965).","journal-title":"Med. J. Aust."},{"key":"1112_CR65","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.31949","volume":"7","author":"JJ Chang","year":"2024","unstructured":"Chang, J. J., Kulkarni, S. & Pasricha, T. S. Upper gastrointestinal mucosal damage and subsequent risk of Parkinson disease. JAMA Netw. Open. 7, e2431949 (2024).","journal-title":"JAMA Netw. Open."},{"key":"1112_CR66","doi-asserted-by":"publisher","first-page":"315","DOI":"10.2310\/6650.2007.00014","volume":"55","author":"V Ozdemir","year":"2007","unstructured":"Ozdemir, V. et al. Cosegregation of gastrointestinal ulcers and schizophrenia in a large national inpatient discharge database: revisiting the \u201cbrain\u2013gut axis\u201d hypothesis in ulcer pathogenesis. J. Investig. Med. 55, 315\u2013320 (2007).","journal-title":"J. Investig. Med."},{"key":"1112_CR67","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1126\/science.1333642","volume":"258","author":"E Mezey","year":"1992","unstructured":"Mezey, E. & Palkovits, M. Localization of targets for anti-ulcer drugs in cells of the immune system. Science 258, 1662\u20131665 (1992).","journal-title":"Science"},{"key":"1112_CR68","doi-asserted-by":"publisher","first-page":"C327","DOI":"10.1152\/ajpcell.00385.2021","volume":"322","author":"XY Liu","year":"2022","unstructured":"Liu, X. Y. et al. Activation of dopamine D2 receptor promotes pepsinogen secretion by suppressing somatostatin release from the mouse gastric mucosa. Am. J. Physiol. Cell Physiol. 322, C327\u2013C337 (2022).","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"1112_CR69","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1159\/000054332","volume":"67","author":"E Mezey","year":"1998","unstructured":"Mezey, E., Eisenhofer, G., Hansson, S., Hunyady, B. & Hoffman, B. J. Dopamine produced by the stomach may act as a paracrine\/autocrine hormone in the rat. Neuroendocrinology 67, 336\u2013348 (1998).","journal-title":"Neuroendocrinology"},{"key":"1112_CR70","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/0016-5085(79)90339-1","volume":"76","author":"SK Lam","year":"1979","unstructured":"Lam, S. K. et al. Treatment of duodenal ulcer with antacid and sulpiride. A double-blind controlled study. Gastroenterology 76, 315\u2013322 (1979).","journal-title":"Gastroenterology"},{"key":"1112_CR71","doi-asserted-by":"publisher","first-page":"PL261","DOI":"10.1016\/0024-3205(94)00843-4","volume":"54","author":"GB Glavin","year":"1994","unstructured":"Glavin, G. B. & Hall, A. M. Clozapine, a dopamine DA4 receptor antagonist, reduces gastric acid secretion and stress-induced gastric mucosal injury. Life Sci. 54, PL261\u2013PL264 (1994).","journal-title":"Life Sci."},{"key":"1112_CR72","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/0091-3057(88)90313-9","volume":"31","author":"GL Willis","year":"1988","unstructured":"Willis, G. L., Sleeman, M., Brodie, G. & Smith, G. C. Observations on dopamine receptor antagonists and gastric ulceration associated with experimental anorexia cachexia. Pharmacol. Biochem. Behav. 31, 69\u201373 (1988).","journal-title":"Pharmacol. Biochem. Behav."},{"key":"1112_CR73","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1211\/0022357991772123","volume":"51","author":"JK Desai","year":"1999","unstructured":"Desai, J. K., Goyal, R. K. & Parmar, N. S. Characterization of dopamine receptor subtypes involved in experimentally induced gastric and duodenal ulcers in rats. J. Pharm. Pharmacol. 51, 187\u2013192 (1999).","journal-title":"J. Pharm. Pharmacol."},{"key":"1112_CR74","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1111\/j.1476-5381.1992.tb09042.x","volume":"105","author":"F Karoum","year":"1992","unstructured":"Karoum, F. & Egan, M. F. Dopamine release and metabolism in the rat frontal cortex, nucleus accumbens, and striatum: a comparison of acute clozapine and haloperidol. Br. J. Pharmacol. 105, 703\u2013707 (1992).","journal-title":"Br. J. Pharmacol."},{"key":"1112_CR75","doi-asserted-by":"publisher","first-page":"105600","DOI":"10.1016\/j.phrs.2021.105600","volume":"170","author":"D Misganaw","year":"2021","unstructured":"Misganaw, D. Heteromerization of dopaminergic receptors in the brain: pharmacological implications. Pharmacol. Res. 170, 105600 (2021).","journal-title":"Pharmacol. Res."},{"key":"1112_CR76","doi-asserted-by":"publisher","DOI":"10.1111\/nmo.13655","volume":"31","author":"H Leng","year":"2019","unstructured":"Leng, H. et al. Regulation of stress-induced gastric ulcers via central oxytocin and a potential mechanism through the VTA-NAc dopamine pathway. Neurogastroenterol. Motil. 31, e13655 (2019).","journal-title":"Neurogastroenterol. Motil."},{"key":"1112_CR77","doi-asserted-by":"publisher","unstructured":"Szabo S., Horner H. C. & Bailey K. A. Neuropharmacologic and biochemical characterization of chemically-induced duodenal ulcer in the rat. In Proc. 7th Int. Congress of Pharmacology Abstract 67 (Elsevier, 1978); https:\/\/doi.org\/10.1016\/B978-0-08-023768-8.50073-6.","DOI":"10.1016\/B978-0-08-023768-8.50073-6"},{"key":"1112_CR78","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1097\/00004647-200202000-00011","volume":"22","author":"V Sossi","year":"2002","unstructured":"Sossi, V. et al. Increase in dopamine turnover occurs early in Parkinson\u2019s disease: evidence from a new modeling approach to PET 18F-fluorodopa data. J. Cereb. Blood Flow. Metab. 22, 232\u2013239 (2002).","journal-title":"J. Cereb. Blood Flow. Metab."},{"key":"1112_CR79","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/0016-5085(91)90528-S","volume":"101","author":"T Takahashi","year":"1991","unstructured":"Takahashi, T., Kurosawa, S., Wiley, J. W. & Owyang, C. Mechanism for the gastrokinetic action of domperidone. In vitro studies in guinea pigs. Gastroenterology 101, 703\u2013710 (1991).","journal-title":"Gastroenterology"},{"key":"1112_CR80","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s40261-015-0360-0","volume":"36","author":"N Leelakanok","year":"2016","unstructured":"Leelakanok, N., Holcombe, A. & Schweizer, M. L. Domperidone and risk of ventricular arrhythmia and cardiac death: a systematic review and meta-analysis. Clin. Drug. Investig. 36, 97\u2013107 (2016).","journal-title":"Clin. Drug. Investig."},{"key":"1112_CR81","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1038\/ncpgasthep0442","volume":"3","author":"PJ Pasricha","year":"2006","unstructured":"Pasricha, P. J., Pehlivanov, N., Sugumar, A. & Jankovic, J. Drug insight: from disturbed motility to disordered movement-a review of the clinical benefits and medicolegal risks of metoclopramide. Nat. Clin. Pract. Gastroenterol. Hepatol. 3, 138\u2013148 (2006).","journal-title":"Nat. Clin. Pract. Gastroenterol. Hepatol."},{"key":"1112_CR82","doi-asserted-by":"publisher","DOI":"10.1111\/nmo.13617","volume":"31","author":"A Al-Saffar","year":"2019","unstructured":"Al-Saffar, A., Lennern\u00e4s, H. & Hellstr\u00f6m, P. M. Gastroparesis, metoclopramide, and tardive dyskinesia: risk revisited. Neurogastroenterol. Motil. 31, e13617 (2019).","journal-title":"Neurogastroenterol. Motil."},{"key":"1112_CR83","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/S0022-3565(25)39116-0","volume":"242","author":"J Wiley","year":"1987","unstructured":"Wiley, J. & Owyang, C. Dopaminergic modulation of rectosigmoid motility: action of domperidone. J. Pharmacol. Exp. Ther. 242, 548\u2013551 (1987).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"1112_CR84","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/BF01072326","volume":"23","author":"GA Lanfranchi","year":"1978","unstructured":"Lanfranchi, G. A., Marzio, L., Cortini, C. & Osset, E. M. Motor effect of dopamine on human sigmoid colon. Evidence for specific receptors. Am. J. Dig. Dis. 23, 257\u2013263 (1978).","journal-title":"Am. J. Dig. Dis."},{"key":"1112_CR85","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/0016-5085(91)70008-L","volume":"100","author":"S Kurosawa","year":"1991","unstructured":"Kurosawa, S., Hasler, W. L., Torres, G., Wiley, J. W. & Owyang, C. Characterization of receptors mediating the effects of dopamine on gastric smooth muscle. Gastroenterology 100, 1224\u20131231 (1991).","journal-title":"Gastroenterology"},{"key":"1112_CR86","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/pr.2016.91","volume":"80","author":"MG Zizzo","year":"2016","unstructured":"Zizzo, M. G. et al. Postnatal development of the dopaminergic signaling involved in the modulation of intestinal motility in mice. Pediatr. Res. 80, 440\u2013447 (2016).","journal-title":"Pediatr. Res."},{"key":"1112_CR87","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1523\/JNEUROSCI.3982-03.2004","volume":"24","author":"ZS Li","year":"2004","unstructured":"Li, Z. S., Pham, T. D., Tamir, H., Chen, J. J. & Gershon, M. D. Enteric dopaminergic neurons: definition, developmental lineage, and effects of extrinsic denervation. J. Neurosci. 24, 1330\u20131339 (2004).","journal-title":"J. Neurosci."},{"key":"1112_CR88","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1136\/gutjnl-2023-329685","volume":"72","author":"B Konings","year":"2023","unstructured":"Konings, B. et al. Gastrointestinal syndromes preceding a diagnosis of Parkinson\u2019s disease: testing Braak\u2019s hypothesis using a nationwide database for comparison with Alzheimer\u2019s disease and cerebrovascular diseases. Gut 72, 2103\u20132111 (2023).","journal-title":"Gut"},{"key":"1112_CR89","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1097\/00002826-200603000-00001","volume":"29","author":"T M\u00fcller","year":"2006","unstructured":"M\u00fcller, T. et al. Impact of gastric emptying on levodopa pharmacokinetics in Parkinson disease patients. Clin. Neuropharmacol. 29, 61\u201367 (2006).","journal-title":"Clin. Neuropharmacol."},{"key":"1112_CR90","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.jns.2012.05.010","volume":"319","author":"H Doi","year":"2012","unstructured":"Doi, H. et al. Plasma levodopa peak delay and impaired gastric emptying in Parkinson\u2019s disease. J. Neurol. Sci. 319, 86\u201388 (2012).","journal-title":"J. Neurol. Sci."},{"key":"1112_CR91","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1056\/NEJM198402233100802","volume":"310","author":"JG Nutt","year":"1984","unstructured":"Nutt, J. G., Woodward, W. R., Hammerstad, J. P., Carter, J. H. & Anderson, J. L. The \u201con-off\u201d phenomenon in Parkinson\u2019s disease. Relation to levodopa absorption and transport. N. Engl. J. Med. 310, 483\u2013488 (1984).","journal-title":"N. Engl. J. Med."},{"key":"1112_CR92","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0165-5728(95)00044-3","volume":"60","author":"S Basu","year":"1995","unstructured":"Basu, S., Dasgupta, P. S. & Chowdhury, J. R. Enhanced tumor growth in brain dopamine-depleted mice following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treatment. J. Neuroimmunol. 60, 1\u20138 (1995).","journal-title":"J. Neuroimmunol."},{"key":"1112_CR93","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/87895","volume":"7","author":"S Basu","year":"2001","unstructured":"Basu, S. et al. The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor\/vascular endothelial growth factor. Nat. Med. 7, 569\u2013574 (2001).","journal-title":"Nat. Med."},{"key":"1112_CR94","doi-asserted-by":"publisher","first-page":"luad176","DOI":"10.1210\/jcemcr\/luad176","volume":"2","author":"S Sahota","year":"2024","unstructured":"Sahota, S., Cooper, L., Sirkova, A. & Stojanovic, N. Dopamine agonists as a novel \u201ccure\u201d for autoimmune diabetes. JCEM Case Rep. 2, luad176 (2024).","journal-title":"JCEM Case Rep."},{"key":"1112_CR95","doi-asserted-by":"publisher","first-page":"4349","DOI":"10.1158\/1078-0432.CCR-04-0059","volume":"10","author":"D Chakroborty","year":"2004","unstructured":"Chakroborty, D. et al. Depleted dopamine in gastric cancer tissues: dopamine treatment retards growth of gastric cancer by inhibiting angiogenesis. Clin. Cancer Res. 10, 4349\u20134356 (2004).","journal-title":"Clin. Cancer Res."},{"key":"1112_CR96","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s00432-012-1326-8","volume":"139","author":"D Florou","year":"2013","unstructured":"Florou, D., Papadopoulos, I. N., Fragoulis, E. G. & Scorilas, A. L-Dopa decarboxylase (DDC) constitutes an emerging biomarker in predicting patients\u2019 survival with stomach adenocarcinomas. J. Cancer Res. Clin. Oncol. 139, 297\u2013306 (2013).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"1112_CR97","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1038\/sj.bjc.6605654","volume":"102","author":"CK Kontos","year":"2010","unstructured":"Kontos, C. K., Papadopoulos, I. N., Fragoulis, E. G. & Scorilas, A. Quantitative expression analysis and prognostic significance of L-DOPA decarboxylase in colorectal adenocarcinoma. Br. J. Cancer 102, 1384\u20131390 (2010).","journal-title":"Br. J. Cancer"},{"key":"1112_CR98","doi-asserted-by":"publisher","first-page":"3130","DOI":"10.1158\/0008-5472.CAN-21-4084","volume":"82","author":"Y Chen","year":"2022","unstructured":"Chen, Y. et al. Dopamine signaling promotes tissue-resident memory differentiation of CD8+ T cells and antitumor immunity. Cancer Res. 82, 3130\u20133142 (2022).","journal-title":"Cancer Res."},{"key":"1112_CR99","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/s41531-023-00562-5","volume":"9","author":"SY Kim","year":"2023","unstructured":"Kim, S. Y. et al. Longitudinal study of the inverse relationship between Parkinson\u2019s disease and cancer in Korea. npj Parkinsons Dis. 9, 116 (2023).","journal-title":"npj Parkinsons Dis."},{"key":"1112_CR100","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1016\/j.ejca.2014.06.018","volume":"50","author":"ELH Ong","year":"2014","unstructured":"Ong, E. L. H., Goldacre, R. & Goldacre, M. Differential risks of cancer types in people with Parkinson\u2019s disease: a national record-linkage study. Eur. J. Cancer 50, 2456\u20132462 (2014).","journal-title":"Eur. J. Cancer"},{"key":"1112_CR101","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1089\/rej.2009.0850","volume":"12","author":"S Singh","year":"2009","unstructured":"Singh, S. et al. The expression of CYP2D22, an ortholog of human CYP2D6, in mouse striatum and its modulation in 1-methyl 4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson\u2019s disease phenotype and nicotine-mediated neuroprotection. Rejuvenation Res. 12, 185\u2013197 (2009).","journal-title":"Rejuvenation Res."},{"key":"1112_CR102","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1159\/000321395","volume":"92","author":"I Garcia-Tornad\u00fa","year":"2010","unstructured":"Garcia-Tornad\u00fa, I. et al. New insights into the endocrine and metabolic roles of dopamine D2 receptors gained from the Drd2 mouse. Neuroendocrinology 92, 207\u2013214 (2010).","journal-title":"Neuroendocrinology"},{"key":"1112_CR103","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.cell.2018.08.049","volume":"175","author":"W Han","year":"2018","unstructured":"Han, W. et al. A neural circuit for gut-induced reward. Cell 175, 665\u2013678.e23 (2018).","journal-title":"Cell"},{"key":"1112_CR104","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.physbeh.2011.04.039","volume":"104","author":"A Sclafani","year":"2011","unstructured":"Sclafani, A., Touzani, K. & Bodnar, R. J. Dopamine and learned food preferences. Physiol. Behav. 104, 64\u201368 (2011).","journal-title":"Physiol. Behav."},{"key":"1112_CR105","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.physbeh.2012.02.026","volume":"106","author":"IE de Araujo","year":"2012","unstructured":"de Araujo, I. E., Ferreira, J. G., Tellez, L. A., Ren, X. & Yeckel, C. W. The gut-brain dopamine axis: a regulatory system for caloric intake. Physiol. Behav. 106, 394\u2013399 (2012).","journal-title":"Physiol. Behav."},{"key":"1112_CR106","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1210\/jcem.84.7.5864","volume":"84","author":"DS Goldstein","year":"1999","unstructured":"Goldstein, D. S. et al. Sources and physiological significance of plasma dopamine sulfate. J. Clin. Endocrinol. Metab. 84, 2523\u20132531 (1999).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1112_CR107","doi-asserted-by":"publisher","first-page":"36824","DOI":"10.1074\/jbc.M505560200","volume":"280","author":"B Rub\u00ed","year":"2005","unstructured":"Rub\u00ed, B. et al. Dopamine D2-like receptors are expressed in pancreatic beta cells and mediate inhibition of insulin secretion. J. Biol. Chem. 280, 36824\u201336832 (2005).","journal-title":"J. Biol. Chem."},{"key":"1112_CR108","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1016\/j.bcp.2010.01.029","volume":"79","author":"JE de Leeuw van Weenen","year":"2010","unstructured":"de Leeuw van Weenen, J. E. et al. The dopamine receptor D2 agonist bromocriptine inhibits glucose-stimulated insulin secretion by direct activation of the alpha2-adrenergic receptors in beta cells. Biochem. Pharmacol. 79, 1827\u20131836 (2010).","journal-title":"Biochem. Pharmacol."},{"key":"1112_CR109","doi-asserted-by":"publisher","first-page":"1460253","DOI":"10.3389\/fendo.2025.1460253","volume":"16","author":"Y Kwon","year":"2025","unstructured":"Kwon, Y. et al. Changes in pancreatic levodopa uptake in patients with obesity and new-onset type 2 diabetes: an 18F-FDOPA PET-CT study. Front. Endocrinol. 16, 1460253 (2025).","journal-title":"Front. Endocrinol."},{"key":"1112_CR110","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S0024-3205(97)00599-7","volume":"61","author":"AH Cincotta","year":"1997","unstructured":"Cincotta, A. H., Tozzo, E. & Scislowski, P. W. Bromocriptine\/SKF38393 treatment ameliorates obesity and associated metabolic dysfunctions in obese (ob\/ob) mice. Life Sci. 61, 951\u2013956 (1997).","journal-title":"Life Sci."},{"key":"1112_CR111","doi-asserted-by":"publisher","first-page":"E1038","DOI":"10.1152\/ajpendo.00567.2005","volume":"291","author":"P Kok","year":"2006","unstructured":"Kok, P. et al. Activation of dopamine D2 receptors simultaneously ameliorates various metabolic features of obese women. Am. J. Physiol. Endocrinol. Metab. 291, E1038\u2013E1043 (2006).","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"1112_CR112","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0167-4889(98)00092-5","volume":"1405","author":"Y Liang","year":"1998","unstructured":"Liang, Y., Lubkin, M., Sheng, H., Scislowski, P. W. & Cincotta, A. H. Dopamine agonist treatment ameliorates hyperglycemia, hyperlipidemia, and the elevated basal insulin release from islets of ob\/ob mice. Biochim. Biophys. Acta 1405, 1\u201313 (1998).","journal-title":"Biochim. Biophys. Acta"},{"key":"1112_CR113","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1053\/meta.2001.26741","volume":"50","author":"TL Jetton","year":"2001","unstructured":"Jetton, T. L., Liang, Y. & Cincotta, A. H. Systemic treatment with sympatholytic dopamine agonists improves aberrant beta-cell hyperplasia and GLUT2, glucokinase, and insulin immunoreactive levels in ob\/ob mice. Metabolism 50, 1377\u20131384 (2001).","journal-title":"Metabolism"},{"key":"1112_CR114","doi-asserted-by":"publisher","first-page":"1532414","DOI":"10.3389\/fendo.2025.1532414","volume":"16","author":"Z Freyberg","year":"2025","unstructured":"Freyberg, Z. & Codario, R. A. Biological mechanisms of dopamine D2-like receptor agonist therapy in diabetes. Front. Endocrinol. 16, 1532414 (2025).","journal-title":"Front. Endocrinol."},{"key":"1112_CR115","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1001\/archinternmed.2009.207","volume":"169","author":"LL Lipscombe","year":"2009","unstructured":"Lipscombe, L. L. et al. Antipsychotic drugs and hyperglycemia in older patients with diabetes. Arch. Intern. Med. 169, 1282\u20131289 (2009).","journal-title":"Arch. Intern. Med."},{"key":"1112_CR116","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/S0140-6736(00)03643-6","volume":"357","author":"GJ Wang","year":"2001","unstructured":"Wang, G. J. et al. Brain dopamine and obesity. Lancet 357, 354\u2013357 (2001).","journal-title":"Lancet"},{"key":"1112_CR117","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.npep.2018.07.003","volume":"71","author":"L Zhang","year":"2018","unstructured":"Zhang, L., Zhang, L., Li, L. & H\u00f6lscher, C. Neuroprotective effects of the novel GLP-1 long acting analogue semaglutide in the MPTP Parkinson\u2019s disease mouse model. Neuropeptides 71, 70\u201380 (2018).","journal-title":"Neuropeptides"},{"key":"1112_CR118","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.neuropharm.2017.02.013","volume":"117","author":"J Jalewa","year":"2017","unstructured":"Jalewa, J., Sharma, M. K., Gengler, S. & H\u00f6lscher, C. A novel GLP-1\/GIP dual receptor agonist protects from 6-OHDA lesion in a rat model of Parkinson\u2019s disease. Neuropharmacology 117, 238\u2013248 (2017).","journal-title":"Neuropharmacology"},{"key":"1112_CR119","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1056\/NEJMoa2312323","volume":"390","author":"WG Meissner","year":"2024","unstructured":"Meissner, W. G. et al. Trial of lixisenatide in early Parkinson\u2019s disease. N. Engl. J. Med. 390, 1176\u20131185 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1112_CR120","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1210\/me.2014-1273","volume":"29","author":"A Maffei","year":"2015","unstructured":"Maffei, A., Segal, A. M., Alvarez-Perez, J. C., Garcia-Oca\u00f1a, A. & Harris, P. E. Anti-incretin, anti-proliferative action of dopamine on \u03b2-cells. Mol. Endocrinol. 29, 542\u2013557 (2015).","journal-title":"Mol. Endocrinol."},{"key":"1112_CR121","doi-asserted-by":"publisher","first-page":"G1326","DOI":"10.1152\/ajpgi.00476.2009","volume":"299","author":"P Kuo","year":"2010","unstructured":"Kuo, P. et al. Effects of metoclopramide on duodenal motility and flow events, glucose absorption, and incretin hormone release in response to intraduodenal glucose infusion. Am. J. Physiol. Gastrointest. Liver Physiol. 299, G1326\u2013G1333 (2010).","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"1112_CR122","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1002\/j.1552-4604.1994.tb03971.x","volume":"34","author":"G Martin","year":"1994","unstructured":"Martin, G. et al. Dopamine-induced antihypertensive effects and plasma insulin rise are blocked by metoclopramide in labetalol-treated patients. J. Clin. Pharmacol. 34, 91\u201394 (1994).","journal-title":"J. Clin. Pharmacol."},{"key":"1112_CR123","doi-asserted-by":"publisher","first-page":"4751","DOI":"10.1111\/bph.14057","volume":"174","author":"X Han","year":"2017","unstructured":"Han, X. et al. Dopamine D2 receptor signalling controls inflammation in acute pancreatitis via a PP2A-dependent Akt\/NF-\u03baB signalling pathway. Br. J. Pharmacol. 174, 4751\u20134770 (2017).","journal-title":"Br. J. Pharmacol."},{"key":"1112_CR124","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.molcel.2020.01.022","volume":"78","author":"Y Wu","year":"2020","unstructured":"Wu, Y. et al. Dopamine uses the DRD5-ARRB2-PP2A signaling axis to block the TRAF6-mediated NF-\u03baB pathway and suppress systemic inflammation. Mol. Cell 78, 42\u201356.e6 (2020).","journal-title":"Mol. Cell"},{"key":"1112_CR125","doi-asserted-by":"publisher","first-page":"11607","DOI":"10.1073\/pnas.96.20.11607","volume":"96","author":"Z Yan","year":"1999","unstructured":"Yan, Z., Feng, J., Fienberg, A. A. & Greengard, P. D2 dopamine receptors induce mitogen-activated protein kinase and cAMP response element-binding protein phosphorylation in neurons. Proc. Natl Acad. Sci. USA 96, 11607\u201311612 (1999).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1112_CR126","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1007\/s11481-018-9825-2","volume":"14","author":"RA Nolan","year":"2019","unstructured":"Nolan, R. A., Muir, R., Runner, K., Haddad, E. K. & Gaskill, P. J. Role of macrophage dopamine receptors in mediating cytokine production: implications for neuroinflammation in the context of HIV-associated neurocognitive disorders. J. Neuroimmune Pharmacol. 14, 134\u2013156 (2019).","journal-title":"J. Neuroimmune Pharmacol."},{"key":"1112_CR127","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.bbi.2019.08.191","volume":"82","author":"EA Nickoloff-Bybel","year":"2019","unstructured":"Nickoloff-Bybel, E. A. et al. Dopamine increases HIV entry into macrophages by increasing calcium release via an alternative signaling pathway. Brain Behav. Immun. 82, 239\u2013252 (2019).","journal-title":"Brain Behav. Immun."},{"key":"1112_CR128","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/S0165-5728(02)00280-1","volume":"132","author":"F McKenna","year":"2002","unstructured":"McKenna, F. et al. Dopamine receptor expression on human T- and B-lymphocytes, monocytes, neutrophils, eosinophils and NK cells: a flow cytometric study. J. Neuroimmunol. 132, 34\u201340 (2002).","journal-title":"J. Neuroimmunol."},{"key":"1112_CR129","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1080\/14017430601085948","volume":"41","author":"B Trabold","year":"2007","unstructured":"Trabold, B., Gruber, M. & Fr\u00f6hlich, D. Functional and phenotypic changes in polymorphonuclear neutrophils induced by catecholamines. Scand. Cardiovasc. J. 41, 59\u201364 (2007).","journal-title":"Scand. Cardiovasc. J."},{"key":"1112_CR130","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0039-6060(99)70171-6","volume":"126","author":"S Sookhai","year":"1999","unstructured":"Sookhai, S., Wang, J. H., McCourt, M., O\u2019Connell, D. & Redmond, H. P. Dopamine induces neutrophil apoptosis through a dopamine D-1 receptor-independent mechanism. Surgery 126, 314\u2013322 (1999).","journal-title":"Surgery"},{"key":"1112_CR131","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1159\/000237114","volume":"108","author":"SP Altenburg","year":"1995","unstructured":"Altenburg, S. P. et al. Systemic neutrophilia observed during anaphylactic shock in rats is inhibited by dopaminergic antagonists. Int. Arch. Allergy Immunol. 108, 33\u201338 (1995).","journal-title":"Int. Arch. Allergy Immunol."},{"key":"1112_CR132","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1111\/imm.13550","volume":"167","author":"F Marino","year":"2022","unstructured":"Marino, F. et al. Dopaminergic inhibition of human neutrophils is exerted through D1-like receptors and affected by bacterial infection. Immunology 167, 508\u2013527 (2022).","journal-title":"Immunology"},{"key":"1112_CR133","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jdermsci.2013.03.008","volume":"71","author":"T Mori","year":"2013","unstructured":"Mori, T. et al. D1-like dopamine receptors antagonist inhibits cutaneous immune reactions mediated by Th2 and mast cells. J. Dermatol. Sci. 71, 37\u201344 (2013).","journal-title":"J. Dermatol. Sci."},{"key":"1112_CR134","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/S0024-3205(99)00023-5","volume":"64","author":"M Cosentino","year":"1999","unstructured":"Cosentino, M. et al. Endogenous catecholamine synthesis, metabolism, storage and uptake in human neutrophils. Life Sci. 64, 975\u2013981 (1999).","journal-title":"Life Sci."},{"key":"1112_CR135","first-page":"3553","volume":"81","author":"NR Musso","year":"1996","unstructured":"Musso, N. R., Brenci, S., Setti, M., Indiveri, F. & Lotti, G. Catecholamine content and in vitro catecholamine synthesis in peripheral human lymphocytes. J. Clin. Endocrinol. Metab. 81, 3553\u20133557 (1996).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1112_CR136","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.3001513","volume":"20","author":"N Honke","year":"2022","unstructured":"Honke, N. et al. Endogenously produced catecholamines improve the regulatory function of TLR9-activated B cells. PLoS Biol. 20, e3001513 (2022).","journal-title":"PLoS Biol."},{"key":"1112_CR137","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/s41586-024-07179-5","volume":"628","author":"SA Scott","year":"2024","unstructured":"Scott, S. A., Fu, J. & Chang, P. V. Dopamine receptor D2 confers colonization resistance via microbial metabolites. Nature 628, 180\u2013185 (2024).","journal-title":"Nature"},{"key":"1112_CR138","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.cell.2019.03.036","volume":"177","author":"H Chen","year":"2019","unstructured":"Chen, H. et al. A forward chemical genetic screen reveals gut microbiota metabolites that modulate host physiology. Cell 177, 1217\u20131231.e18 (2019).","journal-title":"Cell"},{"key":"1112_CR139","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.bbr.2015.05.052","volume":"291","author":"S Sharma","year":"2015","unstructured":"Sharma, S., Taliyan, R. & Singh, S. Beneficial effects of sodium butyrate in 6-OHDA induced neurotoxicity and behavioral abnormalities: modulation of histone deacetylase activity. Behav. Brain Res. 291, 306\u2013314 (2015).","journal-title":"Behav. Brain Res."},{"key":"1112_CR140","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s12974-022-02510-1","volume":"19","author":"P Sittipo","year":"2022","unstructured":"Sittipo, P., Choi, J., Lee, S. & Lee, Y. K. The function of gut microbiota in immune-related neurological disorders: a review. J. Neuroinflamm. 19, 154 (2022).","journal-title":"J. Neuroinflamm."},{"key":"1112_CR141","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.celrep.2017.12.058","volume":"22","author":"A Luqman","year":"2018","unstructured":"Luqman, A., Nega, M., Nguyen, M. T., Ebner, P. & G\u00f6tz, F. SadA-expressing staphylococci in the human gut show increased cell adherence and internalization. Cell Rep. 22, 535\u2013545 (2018).","journal-title":"Cell Rep."},{"key":"1112_CR142","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1023\/A:1013256629600","volume":"47","author":"F Magro","year":"2002","unstructured":"Magro, F. et al. Impaired synthesis or cellular storage of norepinephrine, dopamine, and 5-hydroxytryptamine in human inflammatory bowel disease. Dig. Dis. Sci. 47, 216\u2013224 (2002).","journal-title":"Dig. Dis. Sci."},{"key":"1112_CR143","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1053\/j.gastro.2004.03.013","volume":"126","author":"MD Coates","year":"2004","unstructured":"Coates, M. D. et al. Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome. Gastroenterology 126, 1657\u20131664 (2004).","journal-title":"Gastroenterology"},{"key":"1112_CR144","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1111\/j.1365-201X.2004.01260.x","volume":"180","author":"F Magro","year":"2004","unstructured":"Magro, F., Fraga, S., Ribeiro, T. & Soares-da-Silva, P. Decreased availability of intestinal dopamine in transmural colitis may relate to inhibitory effects of interferon-\u03b3 upon L-DOPA uptake. Acta Physiol. Scand. 180, 379\u2013386 (2004).","journal-title":"Acta Physiol. Scand."},{"key":"1112_CR145","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-03778-6","volume":"12","author":"L Liu","year":"2021","unstructured":"Liu, L. et al. DA-DRD5 signaling controls colitis by regulating colonic M1\/M2 macrophage polarization. Cell Death Dis. 12, 500 (2021).","journal-title":"Cell Death Dis."},{"key":"1112_CR146","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.jcmgh.2021.04.006","volume":"12","author":"F Osorio-Barrios","year":"2021","unstructured":"Osorio-Barrios, F. et al. The heteromeric complex formed by dopamine receptor D5 and CCR9 leads the gut homing of CD4+ T cells upon inflammation. Cell Mol. Gastroenterol. Hepatol. 12, 489\u2013506 (2021).","journal-title":"Cell Mol. Gastroenterol. Hepatol."},{"key":"1112_CR147","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1038\/s41385-020-00354-7","volume":"14","author":"V Ugalde","year":"2021","unstructured":"Ugalde, V. et al. Dopaminergic signalling limits suppressive activity and gut homing of regulatory T cells upon intestinal inflammation. Mucosal Immunol. 14, 652\u2013666 (2021).","journal-title":"Mucosal Immunol."},{"key":"1112_CR148","doi-asserted-by":"publisher","first-page":"4143","DOI":"10.4049\/jimmunol.1502420","volume":"196","author":"F Contreras","year":"2016","unstructured":"Contreras, F. et al. Dopamine receptor D3 signaling on CD4+ T cells favors Th1- and Th17-mediated immunity. J. Immunol. 196, 4143\u20134149 (2016).","journal-title":"J. Immunol."},{"key":"1112_CR149","doi-asserted-by":"publisher","first-page":"981","DOI":"10.3389\/fimmu.2019.00981","volume":"10","author":"D Elgueta","year":"2019","unstructured":"Elgueta, D. et al. Dopamine receptor D3 expression is altered in CD4+ T-cells from Parkinson\u2019s disease patients and its pharmacologic inhibition attenuates the motor impairment in a mouse model. Front. Immunol. 10, 981 (2019).","journal-title":"Front. Immunol."},{"key":"1112_CR150","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.3748\/wjg.v13.i15.2150","volume":"13","author":"A Karban","year":"2007","unstructured":"Karban, A. & Eliakim, R. Effect of smoking on inflammatory bowel disease: is it disease or organ specific? World J. Gastroenterol. 13, 2150\u20132152 (2007).","journal-title":"World J. Gastroenterol."},{"key":"1112_CR151","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.tins.2004.06.008","volume":"27","author":"M Quik","year":"2004","unstructured":"Quik, M. Smoking, nicotine and Parkinson\u2019s disease. Trends Neurosci. 27, 561\u2013568 (2004).","journal-title":"Trends Neurosci."},{"key":"1112_CR152","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1212\/WNL.0000000000000879","volume":"83","author":"B Ritz","year":"2014","unstructured":"Ritz, B., Lee, P. C., Lassen, C. F. & Arah, O. A. Parkinson disease and smoking revisited: ease of quitting is an early sign of the disease. Neurology 83, 1396\u20131402 (2014).","journal-title":"Neurology"},{"key":"1112_CR153","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.dld.2018.09.017","volume":"51","author":"F Zhu","year":"2019","unstructured":"Zhu, F. et al. The risk of Parkinson\u2019s disease in inflammatory bowel disease: a systematic review and meta-analysis. Dig. Liver Dis. 51, 38\u201342 (2019).","journal-title":"Dig. Liver Dis."},{"key":"1112_CR154","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1097\/MIB.0000000000000735","volume":"22","author":"JC Lin","year":"2016","unstructured":"Lin, J. C., Lin, C. S., Hsu, C. W., Lin, C. L. & Kao, C. H. Association between Parkinson\u2019s disease and inflammatory bowel disease: a nationwide Taiwanese retrospective cohort study. Inflamm. Bowel Dis. 22, 1049\u20131055 (2016).","journal-title":"Inflamm. Bowel Dis."},{"key":"1112_CR155","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.parkreldis.2018.02.008","volume":"50","author":"A Camacho-Soto","year":"2018","unstructured":"Camacho-Soto, A., Gross, A., Searles Nielsen, S., Dey, N. & Racette, B. A. Inflammatory bowel disease and risk of Parkinson\u2019s disease in Medicare beneficiaries. Parkinsonism Relat. Disord. 50, 23\u201328 (2018).","journal-title":"Parkinsonism Relat. Disord."},{"key":"1112_CR156","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/j.parkreldis.2014.06.001","volume":"20","author":"MC Hechtner","year":"2014","unstructured":"Hechtner, M. C. et al. Quality of life in Parkinson\u2019s disease patients with motor fluctuations and dyskinesias in five European countries. Parkinsonism Relat. Disord. 20, 969\u2013974 (2014).","journal-title":"Parkinsonism Relat. Disord."},{"key":"1112_CR157","doi-asserted-by":"publisher","first-page":"436","DOI":"10.3390\/biomedicines10020436","volume":"10","author":"S Hamamah","year":"2022","unstructured":"Hamamah, S., Aghazarian, A., Nazaryan, A., Hajnal, A. & Covasa, M. Role of microbiota-gut-brain axis in regulating dopaminergic signaling. Biomedicines 10, 436 (2022).","journal-title":"Biomedicines"},{"key":"1112_CR158","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-08294-y","volume":"10","author":"SP van Kessel","year":"2019","unstructured":"van Kessel, S. P. et al. Gut bacterial tyrosine decarboxylases restrict levels of levodopa in the treatment of Parkinson\u2019s disease. Nat. Commun. 10, 310 (2019).","journal-title":"Nat. Commun."},{"key":"1112_CR159","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1211\/jpp.61.10.0005","volume":"61","author":"M Niehues","year":"2009","unstructured":"Niehues, M. & Hensel, A. In-vitro interaction of L-dopa with bacterial adhesins of Helicobacter pylori: an explanation for clinicial differences in bioavailability? J. Pharm. Pharmacol. 61, 1303\u20131307 (2009).","journal-title":"J. Pharm. Pharmacol."},{"key":"1112_CR160","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1002\/mds.25522","volume":"28","author":"A Fasano","year":"2013","unstructured":"Fasano, A. et al. The role of small intestinal bacterial overgrowth in Parkinson\u2019s disease. Mov. Disord. 28, 1241\u20131249 (2013).","journal-title":"Mov. Disord."},{"key":"1112_CR161","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0251042","volume":"16","author":"P Lolekha","year":"2021","unstructured":"Lolekha, P., Sriphanom, T. & Vilaichone, R. K. Helicobacter pylori eradication improves motor fluctuations in advanced Parkinson\u2019s disease patients: a prospective cohort study (HP-PD trial). PLoS ONE 16, e0251042 (2021).","journal-title":"PLoS ONE"},{"key":"1112_CR162","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1212\/01.wnl.0000221672.01272.ba","volume":"66","author":"M Pierantozzi","year":"2006","unstructured":"Pierantozzi, M. et al. Helicobacter pylori eradication and l-dopa absorption in patients with PD and motor fluctuations. Neurology 66, 1824\u20131829 (2006).","journal-title":"Neurology"},{"key":"1112_CR163","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1097\/WNF.0000000000000037","volume":"37","author":"E Naro\u017ca\u0144ska","year":"2014","unstructured":"Naro\u017ca\u0144ska, E. et al. Pharmacokinetics of levodopa in patients with Parkinson disease and motor fluctuations depending on the presence of Helicobacter pylori infection. Clin. Neuropharmacol. 37, 96\u201399 (2014).","journal-title":"Clin. Neuropharmacol."}],"container-title":["Nature Reviews Gastroenterology & Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41575-025-01112-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41575-025-01112-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41575-025-01112-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T12:02:27Z","timestamp":1758801747000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41575-025-01112-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,8]]},"references-count":163,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["1112"],"URL":"https:\/\/doi.org\/10.1038\/s41575-025-01112-5","relation":{},"ISSN":["1759-5045","1759-5053"],"issn-type":[{"value":"1759-5045","type":"print"},{"value":"1759-5053","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,8]]},"assertion":[{"value":"6 August 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}